Pediatric B-cell lymphomas, such as Burkitt lymphoma and diffuse
large B-cell lymphoma, are usually cured with chemotherapy. However, for
patients with lymphoma that does not respond to chemotherapy or that comes back
after initial treatment, a cure can be difficult to achieve. CAR (chimeric
antigen receptor) T-cell therapy is a promising new treatment for these
challenging cases of pediatric non-Hodgkin
lymphoma. It works by modifying the patient's own
T-cells, a normal part of the body’s immune system, to make cells that hunt and
destroy the abnormal cancer cells.
Learn more about CAR T-cell therapy.
Dana-Farber/Boston Children’s is a certified treatment
center for providing commercially available KYMRIAH, an FDA-approved CAR T-cell
therapy, to patients who are 18 years and older with relapsed or refractory
large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), high
grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
For more information about whether KYMRIAH is right for
your child or to refer a patient, contact:
Colleen Dansereau, RN
Director of Clinical Operations, Gene Therapy Program
Dana-Farber/Boston Children’s also has an open clinical trial available to provide KYMRIAH for children
and adolescents with relapsed or refractory B-cell lymphomas, including Burkitt lymphoma, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma (PMBCL), gray zone lymphoma (GZL), and follicular lymphoma (FL). Participants must be under the age of 18.
Clinical trials are patient studies that test new treatments and therapies. Learn more about participating in clinical trials at Dana-Farber/Boston Children's.
For more information
about whether you or your child is eligible for the clinical trial of KYMRIAH, contact email@example.com.
Get answers to frequently asked questions about KYMRIAH and CAR T-cell therapy.